| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8399508 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Sep, 2022
(1 year, 7 months ago) | |
| US7977376 | NOVARTIS | Olopatadine formulations for topical nasal administration |
Feb, 2023
(1 year, 2 months ago) | |
|
US8399508 (Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Mar, 2023
(1 year, 1 month ago) | |
|
US7977376 (Pediatric) | NOVARTIS | Olopatadine formulations for topical nasal administration |
Aug, 2023
(8 months ago) | |
Patanase is owned by Novartis.
Patanase contains Olopatadine Hydrochloride.
Patanase has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Patanase are:
- US8399508
- US7977376
- US8399508*PED
- US7977376*PED
Patanase was authorised for market use on 15 April, 2008.
Patanase is available in spray, metered;nasal dosage forms.
Patanase can be used as allergic rhinitis.
The generics of Patanase are possible to be released after 02 August, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 01, 2013 |
| New Patient Population(NPP) | Dec 01, 2012 |
Drugs and Companies using
OLOPATADINE HYDROCHLORIDE ingredient
Market Authorisation Date:
15 April, 2008Treatment:
Allergic rhinitisDosage:
SPRAY, METERED;NASAL
How can I launch a generic of PATANASE before its drug patent expiration?
More Information on Dosage
PATANASE family patents
